Kidney Disease Clinical Trials

531 recruitingLast updated: June 18, 2026

There are 531 actively recruiting kidney disease clinical trials across 80 countries. Studies span Not Applicable, Phase 2, Phase 3, Phase 4, Phase 1, Early Phase 1. Top locations include Chicago, Illinois, United States, Dallas, Texas, United States, Philadelphia, Pennsylvania, United States. Updated daily from ClinicalTrials.gov.


Kidney Disease Trials at a Glance

531 actively recruiting trials for kidney disease are listed on ClinicalTrialsFinder across 6 cities in 80 countries. The largest study group is Not Applicable with 159 trials, with the heaviest enrollment activity in Chicago, Dallas, and Philadelphia. Lead sponsors running kidney disease studies include AstraZeneca, University of Colorado, Denver, and VA Office of Research and Development.

Browse kidney disease trials by phase

Treatments under study

About Kidney Disease Clinical Trials

Looking for clinical trials for Kidney Disease? There are currently 35 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Kidney Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Kidney Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 531 trials

Recruiting

A Natural History Study of Metabolic Sizing in Health and Disease

CancerDiabetesChronic Kidney Disease+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)2,000 enrolled1 locationNCT05398783
Recruiting
Phase 1

Adia Med of Winter Park LLC Chronic Kidney Disease Research Study

Kidney Disease, ChronicChronic Kidney DiseaseKidney Disease+2 more
Adia Med of Winter Park LLC100 enrolled1 locationNCT07572890
Recruiting
Not Applicable

Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)

Type 2 Diabetes Mellitus (T2DM)Chronic Kidney Disease(CKD)Type 2 DM
Duke University420 enrolled7 locationsNCT06906640
Recruiting
Not Applicable

Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)

Type 2 Diabetes Mellitus (T2DM)Chronic Kidney Disease(CKD)Type 2 DM
Duke University750 enrolled7 locationsNCT06906627
Recruiting
Not Applicable

Pivotal Study of the Velocity™ pAVF System

Chronic Kidney DiseaseEnd Stage Renal Disease (ESRD)Hemodialysis Access+1 more
Venova Medical126 enrolled12 locationsNCT07153939
Recruiting

ARPKD Database Study

Autosomal Recessive Polycystic Kidney DiseaseNephronophthisisCongenital Hepatic Fibrosis+7 more
Children's Hospital of Philadelphia200 enrolled6 locationsNCT01401998
Recruiting

An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea

Chronic Kidney DiseaseType 2 Diabetes Mellitus
Bayer500 enrolled1 locationNCT07232537
Recruiting
Phase 2

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

IgA Nephropathy (IgAN)IgANC3G+2 more
ADARx Pharmaceuticals, Inc.45 enrolled29 locationsNCT06989359
Recruiting
Phase 2

Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

Autosomal Dominant Polycystic Kidney Disease (ADPKD
Vertex Pharmaceuticals Incorporated24 enrolled43 locationsNCT07161037
Recruiting
Phase 3

A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

Kidney Disease
Takeda347 enrolled169 locationsNCT06963827
Recruiting

Reference Values for Lower-Limb Dynamometry in Patients With Chronic Kidney Disease (REHAD-CKD)

Chronic Kidney Disease on Hemodialysis
Cardenal Herrera University50 enrolled1 locationNCT07642778
Recruiting

Precision Medicine Approaches to Renal Osteodystrophy

Chronic Kidney DiseasesCkd-MbdSecondary Hyperparathyroidism+2 more
Thomas Nickolas40 enrolled1 locationNCT05880914
Recruiting
Phase 2

Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus

Chronic Kidney DiseasesPruritus
Vifor Fresenius Medical Care Renal Pharma18 enrolled16 locationsNCT06593392
Recruiting
Phase 3

A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

Chronic Kidney Disease
Boehringer Ingelheim120 enrolled102 locationsNCT07107945
Recruiting
Early Phase 1

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CTX001 in Healthy Adults.

Chronic Kidney DiseaseIron DeficienciesAnemia
Cajal Therapeutics Inc.72 enrolled1 locationNCT07577817
Recruiting
Not Applicable

Theory-based Health Behaviour Change Intervention in Patients of Metabolic Syndrome With Chronic Kidney Disease

Metabolic SyndromeChronic Kidney Diseases
Chinese University of Hong Kong40 enrolled1 locationNCT06527768
Recruiting
Phase 3

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

Kidney Disease, Chronic
Boehringer Ingelheim11,000 enrolled475 locationsNCT06531824
Recruiting
Phase 4

Mechanism of SGLT2 Inhibition in the Kidney

Type 2 DiabetesDiabetic Kidney Disease
University of Michigan20 enrolled1 locationNCT06291155
Recruiting
Not Applicable

Theory-based Health Behaviour Change Intervention in Individuals of Metabolic Syndrome With Chronic Kidney Disease

Metabolic SyndromeChronic Kidney Diseases
Chinese University of Hong Kong160 enrolled1 locationNCT06715735
Recruiting
Phase 2

PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease

Proteinuric Kidney Diseases
Boehringer Ingelheim132 enrolled156 locationsNCT07355296